Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
146 hedge funds and large institutions have $383M invested in Sciclone Pharmaceuticals Inc in 2015 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 48 reducing their positions, and 7 closing their positions.
51,500% more call options, than puts
Call options by funds: $516K | Put options by funds: $1K
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
27% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 48
21% more capital invested
Capital invested by funds: $316M → $383M (+$67.4M)
12% more funds holding
Funds holding: 130 → 146 (+16)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$8.39M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$4.65M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.16M |
| 4 |
Morgan Stanley
New York
|
+$2.41M |
| 5 |
Renaissance Technologies
New York
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
-$4.81M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4.18M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$1.75M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.56M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.12M |
SCLN Hedge Fund Activity: Q2 2015 in Review
146 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q2 2015, worth a combined $383M — up 21% from $316M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new SCLN positions and 7 closed out — a net gain of 16 holders — while 61 added to existing stakes and 48 trimmed.
The largest buyer was State Street, adding an estimated $8.39M. The largest seller was McKinley Capital Management, exiting entirely with an estimated $4.81M sold.
- 146 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q2 2015, up from 130 in Q1 2015.
- Funds reported $383M of Sciclone Pharmaceuticals Inc stock for Q2 2015, up 21% quarter-over-quarter.
- 23 funds opened new Sciclone Pharmaceuticals Inc positions in Q2 2015 and 7 closed out, a net change of +16 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q2 2015 was State Street, an estimated $8.39M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q2 2015 was McKinley Capital Management, an estimated $4.81M sold.
Based on aggregated 13F filings for Q2 2015.